Found: 4
Select item for more details and to access through your institution.
Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1351739
- By:
- Publication type:
- Article
Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy.
- Published in:
- Cancers, 2022, v. 14, n. 5, p. 1327, doi. 10.3390/cancers14051327
- By:
- Publication type:
- Article
Statin Intolerance, Anti‐HMGCR Antibodies, and Immune Checkpoint Inhibitor‐Associated Myositis: A "Two‐Hit" Autoimmune Toxicity or Clinical Predisposition?
- Published in:
- Oncologist, 2020, v. 25, n. 8, p. e1242, doi. 10.1634/theoncologist.2019-0911
- By:
- Publication type:
- Article
Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
- Published in:
- Oncologist, 2020, v. 25, n. 6, p. 515, doi. 10.1634/theoncologist.2019-0814
- By:
- Publication type:
- Article